EMISPHERE TECHNOLOGIES
Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere currently has a number of product candidates in its pipeline at varying stages. There are multiple product candidates in clinical development as well as several pre-clinical development/research programs. The Company considers specific criteria when deciding whether to devote resources to a development program. The markets that Emisphere seeks to ent... er for a potential product should be substantial. The product candidate should meet a clear unmet medical or market need and the product profile should clearly differentiate Emisphere's products. The Company also considers the level of product development effort in relation to a reasonable return on investment within an acceptable timeframe.
EMISPHERE TECHNOLOGIES
Industry:
Biotechnology Clinical Trials Health Care Pharmaceutical
Founded:
1986-01-01
Address:
Roseland, New Jersey, United States
Country:
United States
Website Url:
http://www.emisphere.com
Total Employee:
51+
Status:
Active
Contact:
9735328017
Email Addresses:
[email protected]
Total Funding:
42.5 M USD
Technology used in webpage:
SPF Font Awesome Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS YouTube Google Google Cloud AWS Global Accelerator
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
FORMA Therapeutics
FORMA Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of transformative medicines.
Immutep
Immutep is a biopharmaceutical company developing immunotherapeutics in oncology.
NovaBay Pharmaceuticals
NovaBay Pharmaceuticals is a biopharmaceutical company developing products for the eye care market.
Parnell Living Science
Parnell is a fully integrated pharmaceutical company dedicated to finding animal health solutions that matter.
Recro Pharma
Recro Pharma is a pharmaceutical company developing non-opioid therapeutics for the treatment of pain.
X4 Pharmaceuticals
X4 Pharmaceuticals a clinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment.
Current Employees Featured
Founder
Stock Details
Official Site Inspections
http://www.emisphere.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Emisphere Technologies"
Emisphere Technologies - Crunchbase Company Profile โฆ
Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere โฆSee details»
Emisphere Technologies - Pharmaceutical Technology
Emisphere Technologies - LinkedIn
Emisphere Technologies | 472 followers on LinkedIn. ... Kowa Pharmaceuticals America, Inc. Pharmaceutical Manufacturing Montgomery, AlabamaSee details»
Emisphere Technologies - Craft
Dec 8, 2020 Emisphere Technologies is a commercial-stage pharmaceutical and drug delivery company. It develops the Eligen drug delivery technology that facilitates oral absorption of โฆSee details»
Emisphere Technologies - Funding, Financials, Valuation & Investors
Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. New. Resources. ... How much funding has this โฆSee details»
Organization | Emisphere Technologies, Inc. - Purdue University
Emisphere Technologies, Inc. Report issue. For profit Phase 1. Founded: Roseland NJ United States (1986 ... Organization Overview. First Clinical Trial. 2001 NCT00982254. First โฆSee details»
Emisphere Technologies - Contacts, Employees, Board Members, โฆ
Emisphere is a pharmaceutical company utilizing its proprietary Eligen Technology to create new oral formulations of therapeutic agents. ... Experience the new Crunchbase, powered by AI . โฆSee details»
Emisphere Technologies - News, Articles etc. - European โฆ
Nov 12, 2020 News stories and articles referencing Emisphere Technologies on European Pharmaceutical Review Recommended Explore the six core considerations for success in โฆSee details»
Emisphere Technologies, Inc - VentureRadar
Find out more about Emisphere Technologies, Inc, Drug Delivery, Drug Delivery and Formulation, Formulation and Delivery and Food and Nutrition. All; Ranked; Organisation Names; Apps and โฆSee details»
Emisphere Technologies, Inc. (Emisphere Technologies, Inc.) - ่ฏ็ฉ โฆ
This is apparent in the 2020/21 transaction whereby Novo Nordisk paid US$1.8 billion to acquire Emisphere Technologies Inc. Emisphere® developed a drug delivery technology now known โฆSee details»
Novo Nordisk Completes Acquisition of Emisphere - GlobeNewswire
Dec 8, 2020 The Emisphere Board of Directors and its Special Committee are confident that this transaction has delivered substantial value to our stockholders,โ said Timothy G. Rothwell, โฆSee details»
Emisphere - Company Profile - Tracxn
Feb 25, 2025 Emisphere Technologies is a commercial stage, specialty pharmaceutical company. The Company is currently preparing to launch its first prescription product, oral โฆSee details»
Emisphere Technologies (EMIS) Stock Price, News & Analysis
1 day ago Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral โฆSee details»
Novo Nordisk acquisition of Emisphere Technologies
Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management โฆSee details»
Emisphere Technologies - Clinical Trials Arena
Emisphere Technologies can integrate Eligen® into a formula whether the drug is in its first developmental stages, in a very advanced phase, or has already received regulatory approval. โฆSee details»
Novo Nordisk lays out $1.8B for Emisphere and its oral delivery tech
Nov 6, 2020 Novo plans to acquire all outstanding shares of Emisphere for $1.35 billion and will take over royalty obligations on Eligen SNAC, worth $450 million, to Emisphere's largest โฆSee details»
Emisphere Provides Development Update on Novo Nordisk Drug โฆ
Emisphere Technologies, Inc. is a drug delivery company that utilizes its proprietary Eligen Technology to develop new oral formulations of therapeutic agents. Emisphere is currently โฆSee details»
Emisphere Launches Eligen B12, the First Oral Prescription Tablet ...
The launch of Eligen B12 marks a turning point for Emisphere as it advances into a well-calculated commercial expansion strategy. Eligen B12โs commercialisation has been precisely โฆSee details»
Emisphere Signs License Agreement with Novo Nordisk to โฆ
The license provides Emisphere with a $5m upfront licensing fee, and the opportunity to receive up to $62.5m in development and sales milestone payments for each of the three exclusively โฆSee details»
Emisphereโs SNAC Carrier Achieves Provisional GRAS Status for โฆ
May 1, 2009 Emisphere Technologies, Inc. (NASDAQ: EMIS) today announced that the company has been informed by an independent expert panel of scientists that its Sodium N-[8 โฆSee details»